Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

Effect of Monotherapy with Darunavir/Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients.

Patients with human immunodeficiency virus type 1 (HIV-1) who receive antiretroviral therapy (ART) often achieve increased survival and improved quality of life. In this respect, monotherapy with darunavir/ritonavir (mDRV/r) can be a useful treatment strategy. This prospective study analyses the eff...

Full description

Bibliographic Details
Main Authors:	Miguel A Lopez-Ruz, Purificación Navas, Miguel A López-Zúñiga, María Carmen Gonzalvo, Antonio Sampedro, Juan Pasquau, Carmen Hidalgo-Tenorio, Rosario Javier, José A Castilla
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4956273?pdf=render

Similar Items

Effect of monotherapy with darunavir/cobicistat on viral load and semen quality of HIV-1 patients.
by: Miguel A López-Ruz, et al.
Published: (2018-01-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)

Antiretroviral simplification with darunavir/ritonavir monotherapy in routine clinical practice: safety, effectiveness, and impact on lipid profile.
by: José R Santos, et al.
Published: (2012-01-01)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

A Case of Possible Darunavir/Ritonavir-Induced Peripheral Neuropathy
by: Margalit Lorber MD
Published: (2013-05-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Comparison of Tolerability and Impact on Metabolic Profiles of Antiretroviral Regimens Containing Darunavir/Ritonavir or Darunavir/Cobicistat in Romanian HIV Infected Patients
by: Ruxandra-Cristina Marin, et al.
Published: (2021-08-01)

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
by: Sidonie Lambert-Niclot, et al.
Published: (2012-01-01)

A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
by: Massimiliano Lanzafame, et al.

A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
by: Massimiliano Lanzafame, MD, et al.
Published: (2011-09-01)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
by: Prakash Manyu, et al.
Published: (2010-05-01)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
by: Anita J Brogan, et al.
Published: (2018-01-01)

Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial
by: Anna Maria Geretti, et al.
Published: (2015-01-01)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens.
by: Luis F López-Cortés, et al.
Published: (2016-01-01)

Long term effect of switching to darunavir/ritonavir in HIV infected patients previously on protease inhibitor therapy
by: Claudio Ucciferri, et al.
Published: (2016-07-01)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
by: Calcagno, A., et al.
Published: (2022)

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study
by: Augusto Di Castelnuovo, et al.
Published: (2021-06-01)

Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years
by: Carmen Hidalgo-Tenorio, et al.
Published: (2021-01-01)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Validation of Simultaneous Quantitative Method of HIV Protease Inhibitors Atazanavir, Darunavir and Ritonavir in Human Plasma by UPLC-MS/MS
by: Tulsidas Mishra, et al.
Published: (2014-01-01)

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
by: Antinori A, et al.
Published: (2016-05-01)

Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
by: Asres Berhan, et al.
Published: (2013-01-01)

Gold in semen: Level in seminal
by: K.P. Skandhan, et al.
Published: (2017-03-01)

Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients.
by: Elżbieta Jabłonowska, et al.
Published: (2019-01-01)

High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
by: Juan Pasquau, et al.
Published: (2018-01-01)

ART is key to clearing oncogenic HPV genotypes (HR-HPV) in anal mucosa of HIV-positive MSM.
by: Carmen Hidalgo-Tenorio, et al.
Published: (2019-01-01)

The Effect of Solvents and Drying Temperature on the Physicochemical Properties of Darunavir and Darunavir Ethanolate Substances
by: S. A. Zolotov, et al.
Published: (2021-02-01)

Characteristics and early outcomes of children and adolescents treated with darunavir/ritonavir raltegravir or etravirinecontaining antiretroviral therapy in the Western Cape Province of South Africa
by: J Nuttall, et al.
Published: (2018-02-01)

Semen decontamination for the elimination of seminal pathogens
by: Fourie, Jozef Markus
Published: (2014)

Virologic and Immunologic Effectiveness at 48 Weeks of Darunavir–Ritonavir-Based Regimens in Treatment-Experienced Persons Living with HIV-1 Infection in Clinical Practice
by: Fernando Martín Biscione MD, PhD, et al.
Published: (2014-01-01)

Assisted Reproductive Technology and Obstetric Outcome in Couples when The Male Partner Has A Chronic Viral Disease
by: Irene Molina, et al.
Published: (2014-01-01)

Some of the influences of seminal vesiculectomy on bovine semen /
by: Hess, Edwin Albiun.
Published: (1957)

Semen Quality and Ferritin and Transferrin Seminal Levels
by: Silva Gilmar Pereira, et al.
Published: (2018-12-01)

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).
by: Charlotte Charpentier, et al.
Published: (2013-01-01)

Desensitization to darunavir in a pediatric patient
by: Julio César Cambray-Gutiérrez, et al.
Published: (2015-07-01)

Risk factors for ≥high-grade anal intraepithelial lesions in MSM living with HIV and the response to topical and surgical treatments.
by: Carmen Hidalgo-Tenorio, et al.
Published: (2021-01-01)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
by: Eduardo Arathoon, et al.
Published: (2017-01-01)

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial.
by: Ajantha Solomon, et al.
Published: (2014-01-01)

Evolutionary Medicine: Semen Sampling and Seminal Plasma Hypersensitivity
by: Gordon G. Gallup, et al.
Published: (2014-01-01)